Publications: Prof Graham Foster

Mahtab MA, Rahman S, Karim MF, Khan M, Foster G, Solaiman S, Afroz S ( 2008 ) . Epidemiology of hepatitis B virus in Bangladeshi general population . HEPATOB PANCREAT DIS vol. 7 , ( 6 ) 595 - 600 .

Uddin G, Faster GR ( 2008 ) . TITLE: PREVALENCE OF CHRONIC VIRAL HEPATITIS IN SOUTH ASIANS IMMIGRANTS - PEOPLE FROM PAKISTAN HAVE HIGH RATES OF INFECTION WITH HEPATITIS C AND HIGH RATES OF HEPATITIS C INDUCED CIRRHOSIS IN MIDDLE AGE . HEPATOLOGY . vol. 48 , 533A - 533A .

Coyle FM, Taylor NF, Monson JP, Drake WM, Foster GR ( 2007 ) . Non-alcoholic fatty liver disease is associated with transcriptional dysregulation of the corticosteroid metabolising enzyme II beta HSD-1 leading to excess intrahepatic steroid exposure . HEPATOLOGY . vol. 46 , 741A - 741A .

Avraamides G, Ng C-Y, David R, Gu Y, Fazekasova H, Mirenda V, Foster GR, Runkel L et al. ( 2007 ) . IFN-alpha2 induces leukocyte integrin redistribution, increased adhesion, and migration . J Interferon Cytokine Res vol. 27 , ( 4 ) 291 - 303 .

Thomas T, Foster G ( 2007 ) . Nanomedicines in the treatment of chronic hepatitis C - focus on pegylated interferon alpha-2a . INT J NANOMED vol. 2 , ( 1 ) 19 - 24 .

Barton A, Choudhury A, Shanmugasundaram P, McAvinia P, Coyle F, Foster G, Kuitert L ( 2006 ) . Association between abnormal hepatic enzymes, fatty change in the liver, and acute pulmonary infection in cystic fibrosis . THORAX . vol. 61 , II121 - II122 .

Jones M, Strang AL, Hibbert L, Smith PL, Jacobs MG, Foster GR ( 2006 ) . HCVNS5A protein - Functional analysis using a BVDV replicon reporter system shows a correlation between in vitro effects on interferon sensitivity and clinical outcome . JOURNAL OF HEPATOLOGY . vol. 44 , S153 - S154 .

Swain MG, Foster G, Hadziyannis S, Heathcote J, Jensen D, Lee S, Pockros P, Sulkowski M et al. ( 2005 ) . Clustering of poor prognostic factors in heavier patients with chronic hepatitis C (CHC): Baseline characteristics and outcomes with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus ribavirin (RBV, COPEGUS (R)) in randomized, international, Phase III trials . HEPATOLOGY . vol. 42 , 687A - 688A .

Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S, Foster GR, Jacobs M ( 2005 ) . Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression . J VIROL vol. 79 , ( 9 ) 5414 - 5420 .

Jones M, Germain C, Lechler RI, Lombardi G, Foster GR ( 2004 ) . Immunomodulatory properties of the type I interferons: Type I interferons can both activate and inhibit Th1 activation . HEPATOLOGY . vol. 40 , 345A - 345A .

Weiland O, Fried MW, Hadziyannis SJ, Foster GR, Messinger D, Freivogel K, Chaneac M ( 2004 ) . Combination therapy with peginterferon alfa-2a (40kd) (PEGASYS (R)) plus ribavirin (COPEGUS (R)) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR) . JOURNAL OF HEPATOLOGY . vol. 40 , 154 - 154 .

D'Souza R, Alstead E, Glynn M, Kumar P, Sabin C, Ushiro-Lumb I, Mears L, Feakins R et al. ( 2004 ) . Natural history of chronic hepatitis C infection: Long term follow up of Asian patients infected in childhood . GUT . vol. 53 , A81 - A82 .

Nkhoma ANS, Macey M, Foster GR ( 2004 ) . Transition from acute to chronic viral infections - A tissue culture model using respiratory syncitial virus infected cells . GUT . vol. 53 , A82 - A82 .

Foster GR, D'Souza RFC, Main J, Crossey M, Rosenberg W, Murray-Lyon IM, Hayward C ( 2003 ) . Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy - Is it worthwhile? . HEPATOLOGY . vol. 38 , 646A - 646A .

Foster GR, Fried MW, Hadziyannis SJ, Chaneac M ( 2003 ) . Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) (PEGASYS (R)) and ribavirin (COPEGUS (R)): Patient age has a marked influence on the individual estimated probability of achieving a sustained virological response . HEPATOLOGY . vol. 38 , 246A - 246A .